01954nas a2200253   4500000000100000008004100001100001200042700001500054700001600069700001200085700001300097700001200110700001200122700001100134700001700145700001600162700001200178245010800190856007500298300001000373490000600383520129700389022001401686       2016                            d1 aHooij A1 aKon Fat ET1 aRichardus R1 aEeden S1 aWilson L1 aDood CJ1 aFaber R1 aAlam K1 aRichardus JH1 aCorstjens P1 aGeluk A00aQuantitative lateral flow strip assays as User-Friendly Tools To Detect Biomarker Profiles For Leprosy.  uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5041085/pdf/srep34260.pdf  a342600 v63 a<p>Leprosy is a debilitating, infectious disease caused by Mycobacterium leprae. Despite the availability of multidrug therapy, transmission is unremitting. Thus, early identification of M. leprae infection is essential to reduce transmission. The immune response to M. leprae is determined by host genetics, resulting in paucibacillary (PB) and multibacillary (MB) leprosy associated with dominant cellular or humoral immunity, respectively. This spectral pathology of leprosy compels detection of immunity to M. leprae to be based on multiple, diverse biomarkers. In this study we have applied quantitative user friendly lateral flow assays (LFAs) for four immune markers (anti-PGL-I antibodies, IL-10, CCL4 and IP-10) for whole blood samples from a longitudinal BCG vaccination field-trial in Bangladesh. Different biomarker profiles, in contrast to single markers, distinguished M. leprae infected from non-infected test groups, patients from household contacts (HHC) and endemic controls (EC), or MB from PB patients. The test protocol presented in this study merging detection of innate, adaptive cellular as well as humoral immunity, thus provides a convenient tool to measure specific biomarker profiles for M. leprae infection and leprosy utilizing a field-friendly technology.</p>
  a2045-2322